Gerhardt Attard is a John Black Charitable Foundation Endowed Chair in Urological Cancer Research at University College London (UCL), in London, UK. He holds an advanced Cancer Research UK Clinician Scientist Award and is Team Leader of the Treatment Resistance Group at the UCL Cancer Institute. Professor Attard graduated with a degree in medicine from the University of Malta, Malta, in 1999, and obtained a PhD in medicine from the Institute of Cancer Research, University of London, in 2010.
Professor Attard’s main research interest is dissecting treatment resistance, currently with a focus on plasma DNA analysis, in order to inform on the development of novel therapeutics and biomarkers for castration-resistant prostate cancer (CRPC). He is an experienced clinical triallist in the field of CRPC, and sits on a number of advisory boards and on the editorial board of Annals of Oncology.
Professor Attard is the recipient of numerous awards over the years including the American Society of Clinical Oncology (ASCO) Foundation Annual Merit Award in 2007, the Prostate Cancer Foundation Young Investigator Award in 2008, the American Association for Cancer Research (AACR)-GlaxoSmithKline Outstanding Clinical Scholar Award in 2009, the Medical Research Society/Academy of Medical Sciences Sue McCarthy Prize in 2010, the McElwain Award in 2010, and more recently, the Cancer Research UK Future Leader Award in 2017. He is co-author of more than 130 peer-reviewed manuscripts, including several important papers on advanced prostate cancer.
EM-60629; Date of preparation: April 2021